Synovial Fibroblast 3.2: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis-diagnosed donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 2 of 2) - Dataset (ID:20235)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
N2645 | Poly(I:C) | 2 | ug/mL | 4 | G-CSF | 87.0 | 52 | ||||
RA2708 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 4 | G-CSF | 88.0 | 47 | |
RA2708 | Poly(I:C) | 2 | ug/mL | 4 | G-CSF | 55.0 | 56 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | G-CSF | 22.0 | 78 | |
RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | G-CSF | 38.0 | 70 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | G-CSF | 21.0 | 68 | |
N2645 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | G-CSF | 27.0 | 68 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | G-CSF | 22.0 | 69 | |
RA2708 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | G-CSF | 51.0 | 71 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | G-CSF | 609.5 | 64 | |
RA2159 | IL-1 alpha | 100 | ng/mL | 4 | G-CSF | 461.5 | 74 | ||||
N2645 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | G-CSF | 59.5 | 58 | |
N2645 | IL-1 alpha | 100 | ng/mL | 4 | G-CSF | 79.0 | 62 | ||||
RA2708 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | G-CSF | 610.5 | 46 | |
RA2708 | IL-1 alpha | 100 | ng/mL | 4 | G-CSF | 709.0 | 70 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | G-CSF | 54.5 | 70 | |
RA2159 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | G-CSF | 57.0 | 48 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | G-CSF | 59.0 | 77 | |
N2645 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | G-CSF | 62.5 | 70 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | G-CSF | 66.0 | 62 | |
RA2708 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | G-CSF | 61.0 | 64 | |
RA2159 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 4 | G-CSF | 63.5 | 78 | |
RA2159 | TNF-a | 100 | ng/mL | 4 | G-CSF | 75.0 | 68 | ||||
N2645 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 4 | G-CSF | 78.0 | 65 | |
N2645 | TNF-a | 100 | ng/mL | 4 | G-CSF | 84.5 | 66 |